Compare ASTRAZENECA PHARMA with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CADILA HEALTHCARE ASTRAZENECA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 141.2 29.7 475.3% View Chart
P/BV x 39.6 4.8 828.4% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
CADILA HEALTHCARE
Mar-20
ASTRAZENECA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,278352 362.8%   
Low Rs883207 427.4%   
Sales per share (Unadj.) Rs228.4139.2 164.1%  
Earnings per share (Unadj.) Rs10.411.8 88.1%  
Cash flow per share (Unadj.) Rs16.318.6 87.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs98.8101.4 97.5%  
Shares outstanding (eoy) m25.001,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.0 235.7%   
Avg P/E ratio x104.223.7 438.9%  
P/CF ratio (eoy) x66.415.0 441.5%  
Price / Book Value ratio x10.92.8 396.7%  
Dividend payout %029.8 0.0%   
Avg Mkt Cap Rs m27,008286,033 9.4%   
No. of employees `0001.413.4 10.1%   
Total wages/salary Rs m1,53524,145 6.4%   
Avg. sales/employee Rs Th4,210.910,632.7 39.6%   
Avg. wages/employee Rs Th1,132.21,801.2 62.9%   
Avg. net profit/employee Rs Th191.1898.5 21.3%   
INCOME DATA
Net Sales Rs m5,710142,531 4.0%  
Other income Rs m1231,139 10.8%   
Total revenues Rs m5,833143,670 4.1%   
Gross profit Rs m46324,198 1.9%  
Depreciation Rs m1476,965 2.1%   
Interest Rs m03,418 0.0%   
Profit before tax Rs m43814,954 2.9%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1793,198 5.6%   
Profit after tax Rs m25912,044 2.2%  
Gross profit margin %8.117.0 47.8%  
Effective tax rate %40.821.4 191.0%   
Net profit margin %4.58.5 53.7%  
BALANCE SHEET DATA
Current assets Rs m3,20987,154 3.7%   
Current liabilities Rs m2,07082,694 2.5%   
Net working cap to sales %20.03.1 637.9%  
Current ratio x1.61.1 147.1%  
Inventory Days Days7271 101.3%  
Debtors Days Days3594 37.2%  
Net fixed assets Rs m790133,236 0.6%   
Share capital Rs m501,024 4.9%   
"Free" reserves Rs m2,419102,733 2.4%   
Net worth Rs m2,469103,757 2.4%   
Long term debt Rs m032,146 0.0%   
Total assets Rs m4,605236,866 1.9%  
Interest coverage xNM5.4-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.6 206.0%   
Return on assets %5.66.5 86.2%  
Return on equity %10.511.6 90.4%  
Return on capital %17.713.7 129.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30052,752 0.6%   
Fx outflow Rs m2,01514,504 13.9%   
Net fx Rs m-1,71538,248 -4.5%   
CASH FLOW
From Operations Rs m8825,054 0.4%  
From Investments Rs m-94-10,123 0.9%  
From Financial Activity Rs mNA-10,942 0.0%  
Net Cashflow Rs m-63,989 -0.1%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 15.7 5.9 266.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   12,856 44,069 29.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SHASUN PHARMA  WYETH  ABBOTT INDIA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Dow Futures Up by 6 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 20, 2021 03:36 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS